本文關(guān)鍵詞： 乳腺癌 分子分型 新輔助化療 預(yù)后　出處：《新疆醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:探討乳腺癌不同分子分型與新輔助化療療效及預(yù)后的相關(guān)性。方法:對新疆醫(yī)科大學(xué)附屬腫瘤醫(yī)院2009年1月至2015年9月間初治的344例新輔助化療乳腺癌患者進(jìn)行回顧性分析,將乳腺癌患者通過免疫組化檢測雌激素受體(ER)、孕激素受體(PR)、人表皮生長因子受體-2(HER-2)的表達(dá)情況,分為Luminal A、Luminal B、HER-2過表達(dá)和Basal-like四類分子亞型,并通過各分子分型對新輔助化療的病理反應(yīng)性分析不同分子亞型乳腺癌與新輔助化療療效及預(yù)后的相關(guān)性。結(jié)果:Luminal A型54例,LuminalB型149例,Her-2過表達(dá)型59例,三陰型82例,其中Luminal A型、LuminalB型、Her-2過表達(dá)型、Basal-Like型的MP5(pCR)率分別為3.5%,1.8%,1.3%、5.3%;Her-2過表達(dá)型及Basal-Like型乳腺癌化療病理顯效率高于Luminal亞型。Luminal A亞型、LuminalB型、Her-2過表達(dá)型、Basal-Like型的5年DFS和OS分別為92.6%、89.3%、71.2%、75.6%,和100%、98.0%、89.8%、93.9%,差異具有統(tǒng)計(jì)學(xué)意義(P=0.000,P=0.016);結(jié)論:相比于Luminal A型,Basal-like型和Her-2過表達(dá)亞型的新輔助化療病理顯效率高,但預(yù)后較差,而Luminal亞型乳腺癌的預(yù)后明顯好于Her-2過表達(dá)型、Basal-Like型。Basa1-1ike亞型和Her-2過表達(dá)亞型的化療敏感性優(yōu)于Luminal亞型,能獲得更好的pCR率。乳腺癌分子分型能作為乳腺癌新輔助化療療效的有效預(yù)測因子。
[Abstract]:Objective: to investigate the correlation between different molecular classification of breast cancer and the curative effect and prognosis of neoadjuvant chemotherapy. Methods: 344 cases of neoadjuvant chemotherapy breast cancer were treated from January 2009 to September 2015 in the affiliated Cancer Hospital of Xinjiang Medical University. For retrospective analysis, The expression of estrogen receptor (ERG), progesterone receptor (PRN) and human epidermal growth factor receptor (EGF) HER-2 were detected by immunohistochemistry in patients with breast cancer. The relationship between different molecular subtypes of breast cancer and the curative effect and prognosis of neoadjuvant chemotherapy was analyzed through the pathological reactivity of different molecular subtypes of neoadjuvant chemotherapy. Results 59 cases of Her-2 overexpression and 82 cases of triple negative type were found in 149 cases of LuminalB type. The rate of MP5pCRs of Luminal A and Her-2 overexpression type Basal-Like type was 3.55.51 and 1.38, respectively, and the pathological efficiency of Basal-Like breast cancer was higher than that of Luminal subtype. Luminal A subtype, LuminalB Her-2 over-expression type and Basal-Like type. The 5 year DFS and OS of Basal-Like type were 92.689.31.2m75.65.6, and 10098.00.89. 889, 93.9, respectively. The difference was significant. Conclusion: compared with Luminal A type and Her-2 overexpression subtype, neoadjuvant chemotherapeutic effect of neo-adjuvant chemotherapy is higher than that of neo-adjuvant chemotherapy. However, the prognosis of Luminal subtype was significantly better than that of Her-2 overexpression type Basal-Like subtype and Her-2 overexpression subtype. The chemosensitivity of Luminal subtype was better than that of Luminal subtype. The molecular classification of breast cancer can be used as an effective predictor of neoadjuvant chemotherapy in breast cancer.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.9

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 牛海飛;魏麗娟;連鎮(zhèn);趙晶;李利娟;吳梓政;劉俊田;;乳腺癌新輔助化療療效與分子分型和預(yù)后的關(guān)系[J];中華腫瘤雜志;2016年03期

2 桑蝶;王佳玉;袁們;馬飛;李青;張頻;樊英;蔡銳剛;羅揚(yáng);李俏;徐兵河;;Ki-67與乳腺癌臨床病理特征及新輔助化療療效的相關(guān)性[J];癌癥進(jìn)展;2015年03期

3 楊文濤;步宏;;乳腺癌新輔助化療后的病理診斷專家共識(shí)[J];中華病理學(xué)雜志;2015年04期

4 邱秀娟;成芳;劉瑩;;新疆1006例維吾爾族與漢族不同分子分型乳腺癌患者的臨床病理特征及生存分析[J];腫瘤;2015年03期

5 王文彥;張柏林;徐曉洲;王昕;張頻;王翔;;新輔助化療后腋窩淋巴結(jié)分期和病理緩解狀態(tài)對乳腺癌患者預(yù)后的影響[J];中華腫瘤雜志;2015年03期

6 謝伯劍;蔡楊俊;鄭中秋;崔斌斌;徐東;曹飛麟;;不同乳腺癌分子分型患者新輔助化療療效的比較[J];浙江醫(yī)學(xué);2015年03期

7 王新昭;左文述;劉琪;于志勇;;2013年St Gallen乳腺癌會(huì)議國際專家共識(shí)薈萃[J];中華腫瘤防治雜志;2013年23期

8 葉國麟;楊R，

本文編號(hào)：1553544